XYRA Announces Successful FDA End of Phase 2 Meeting and Agreement on Endpoints for Approval of Budiodarone for the Management of Atrial Fibrillation

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

XYRA

More Like This

PR Newswire associated0

XYRA Announces the Issuance of a Fifth New US Patent in a Series of Patents Which Protect the Use of Budiodarone in the Management of Atrial Fibrillation till after 2040

PR Newswire associated0

XYRA Announces FDA Label Guidance for Managing Atrial Fibrillation with Budiodarone and Wearable Monitoring Devices

PR Newswire associated0

CardiaCare Completes Seed Extension Raise to Support Clinical Pilot Studies

PR Newswire associated0

AuriGen Medical Pioneers Next-Generation Atrial Fibrillation Technology with First-in-Human Success

Portrait of Dr. Martin Steinhart, CEO AOP Health (Photo: AOP Health/Studio Koekart)

U.S. FDA Approves AOP Health’s RapiblykTM (landiolol) for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting

PR Newswire associated0

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform

Business Wire logo

MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology